AstraZeneca stock heads into the open after a 3.3% London gain
Published on 09/15/2026 at 07:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
AstraZeneca stock closed at 11,708.0 GBX on the London Stock Exchange on September 11, 2026, slipping 0.43% from the prior session. Compared with the recent 12-month range between 10,784.0 GBX and 15,730.0 GBX, the latest close left the shares closer to the lower end of their one-year span.
September 11, 2026 in numbers
AstraZeneca PLC (ISIN US6549022043, London: AZN) recorded a day range between 11,708.0 GBX and 11,960.0 GBX on September 11, 2026, with trading volume at about 1.47 million shares according to London quote data. The 11,708.0 GBX close sat above the session low and below the high, consistent with the reported intraday band. Over the recent period from August 13, 2026 to September 11, 2026, the stock traded between 11,404.0 GBX and 12,476.0 GBX, showing that the latest close was roughly 8.2% below that short-term high of 12,476.0 GBX.
Later in the new week, AstraZeneca shares were described as trading at 12,086.0 GBX in London with a gain of 3.25% on September 14, 2026, indicating a rebound of about 3.2% from the 11,708.0 GBX close on September 11, 2026. As Ad-hoc-news reported on September 14, 2026, the stock gains were linked to favorable Enhertu lung-cancer data that helped offset concerns from the earlier Serena 4 breast-cancer trial setback.
Today’s catalysts and events
Today, investors are watching AstraZeneca after fresh oncology data highlighted Tagrisso’s long-term benefits in early-stage non-small cell lung cancer. On September 14, 2026, GuruFocus noted that updated ADAURA Phase III trial results presented at the IASLC 2026 World Conference on Lung Cancer showed Tagrisso cutting mortality risk by 47% over eight years in EGFR-mutated early-stage disease, reinforcing the drug’s strategic role in AstraZeneca’s oncology portfolio. According to the same report, the ADR price referenced at 160.17 USD with a GF Value estimate of 181.19 USD framed the stock as modestly undervalued ahead of the next phase of data and commercialization milestones.
Broader market conditions also shape the backdrop into today’s session. On September 14, 2026, CNBC reported that major US equity indices slipped modestly as traders weighed rising oil prices and interest rates, a macro setting that can influence sentiment toward large pharmaceutical names. In addition, AstraZeneca featured among the highlighted ideas in a recent segment of CNBC’s investment committee, underscoring that the stock remains on trading desks’ radar for the coming sessions.
